200 Saginaw Drive,
Redwood City, California 94063
Pearl was founded in 2006, with a mission to develop differentiated therapeutics for respiratory disease conditions prevalent worldwide, including chronic obstructive pulmonary disease (COPD). The product candidates currently being developed are based on the simple and widely prescribed metered-dose inhaler (MDI) dosage form. Company scientists have invented a novel cosuspension formulation technology for use with MDIs that enables efficient targeting and distribution of drug to the lungs.
Pearl Therapeutics was acquired by AstraZeneca on June 28, 2013.
Join Mergr to view all 175 acquisitions of life science companies in 2013, including 20 acquisitions by private equity firms, and 155 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2013. The largest life science acquisition in 2013 was Onyx Pharmaceuticals - which was acquired by Amgen for $10.4B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Pearl Therapeutics.
No obligation. Cancel anytime.